Skip to main content

Glucagon-like peptide-1 (GLP-1) receptor agonists


04-28-2020 | GLP-1 agonists | News

Early findings suggest route to GLP-1 receptor agonism with less gastrointestinal discomfort

A phase 1 study of a novel glycosylated Fc-fused glucagon-like peptide-1 receptor agonist suggests it could deliver similar blood glucose-lowering efficacy but with fewer gastrointestinal side effects relative to existing medications in the class.

04-28-2020 | Cardiovascular outcomes | News

Updated analysis shows cardiovascular benefits of type 2 diabetes therapies

Glucose-lowering drugs or strategies reduce the risk for major adverse cardiovascular events and death in people with or at risk for type 2 diabetes, but their impact on heart failure may depend on weight loss, shows an updated systematic review and meta-analysis.

04-24-2020 | Semaglutide | Highlight | News

PIONEER 9, 10 confirm oral semaglutide efficacy in Japanese population

Results of the PIONEER 9 and 10 trials show that oral semaglutide is efficacious in Japanese people with type 2 diabetes.

04-23-2020 | GLP-1 agonists | News

Real-world evidence for renoprotective effects of GLP-1 receptor agonists

People with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists have a lower risk for serious renal adverse events than those given dipeptidyl peptidase-4 inhibitors, indicate results from a Scandinavian real-world study.

03-09-2020 | Liraglutide (T2DM) | News

Liraglutide may reduce CV risk regardless of heart failure

A post-hoc analysis of the LEADER trial suggests that liraglutide reduces cardiovascular risk in people with type 2 diabetes regardless of whether they have heart failure.

03-04-2020 | Exenatide | News

Short-acting exenatide makes little difference to glycemia in type 1 diabetes

Short-acting exenatide “does not seem to have a future” as a standard adjunct treatment in people with type 1 diabetes, say the MAG1C investigators.

02-17-2020 | GLP-1 agonists | News

Novel drug combination shows preclinical diabetes promise

Combining a glucagon-like peptide-1 receptor agonist with an experimental compound could increase the function and numbers of beta cells, suggest preclinical findings in Science Translational Medicine.

01-31-2020 | Cardiovascular outcomes | News

Cardiovascular risks, benefits of different diabetes drugs quantified

An umbrella review of meta-analyses has demonstrated mixed associations between different glucose-lowering agents and cardiovascular outcomes in people with type 2 diabetes, with the results favoring sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists as cardioprotective agents.

01-09-2020 | Stroke | News

REWIND supports stroke protective effect for GLP-1 receptor agonists

An exploratory analysis of stroke outcomes in the REWIND trial indicates that dulaglutide may reduce the incidence but not severity of ischemic stroke in people with type 2 diabetes.

09-23-2019 | Children | EASD 2019 | News

RISE compares alpha, beta cells in youth vs adults with early type 2 diabetes

The failure of intensive medication to halt beta-cell decline in children with early type 2 diabetes occurs despite them having better baseline beta-cell and alpha-cell function than newly diagnosed adults, say the RISE researchers.

09-23-2019 | Liraglutide (T2DM) | EASD 2019 | News

Add-on liraglutide may preserve insulin secretion in type 1 diabetes

Findings from the NewLira trial suggest that addition of the glucagon-like peptide-1 receptor agonist liraglutide to insulin treatment may preserve postprandial insulin secretion among adults with newly diagnosed type 1 diabetes.

09-18-2019 | Semaglutide | EASD 2019 | News

Semaglutide tops liraglutide in SUSTAIN 10

Findings from the SUSTAIN 10 trial show that semaglutide results in better glycemic control than liraglutide when added to oral antidiabetic drugs in people with type 2 diabetes.

09-18-2019 | Semaglutide | EASD 2019 | News

SUSTAIN 8: Semaglutide outperforms canagliflozin as second-line therapy for type 2 diabetes

Treatment with the glucagon-like peptide-1 receptor agonist semaglutide results in better glycemic control than the sodium-glucose cotransporter 2 inhibitor canagliflozin among people with type 2 diabetes uncontrolled on metformin, indicate the SUSTAIN 8 trial results.

09-17-2019 | Semaglutide | EASD 2019 | News

PIONEER data support oral semaglutide across a wide range of patients

Researchers at the 55th EASD Annual Meeting in Barcelona, Spain, have presented primary data and subanalyses from a number of the PIONEER trials investigating the efficacy of oral semaglutide in people with type 2 diabetes.

08-19-2019 | GLP-1 agonists | Highlight | News

Meta-analysis demonstrates cardioprotective effect of GLP-1 receptor agonists

Treatment with glucagon-like peptide receptor agonists reduces the risk for major adverse cardiovascular events among people with type 2 diabetes, indicate findings from a large meta-analysis.

08-09-2019 | Insulin | News

Weight loss differences seen with fixed vs flexible insulin, GLP-1RA regimens

Patients initiating a flexible combination of basal insulin plus a glucagon-like peptide-1 receptor agonist have similar improvements in glycemic control to those initiating a fixed combination, but with greater weight loss, real-world study data show.

07-15-2019 | Medications | News

Second-line type 2 diabetes therapies vary globally

Second-line therapy choices for people with type 2 diabetes vary widely throughout the world and are influenced not only by clinical characteristics but also non-medical factors such as affordability and availability, results from the DISCOVER study show.

06-11-2019 | Semaglutide | ADA 2019 | News

Oral semaglutide falls just short of cardioprotection in event-driven PIONEER 6

The PIONEER 6 trial demonstrates the noninferior cardiovascular safety profile of oral semaglutide compared with placebo, but fails to demonstrate superiority, despite an overall positive trend and significance for cardiovascular death.

06-10-2019 | Dulaglutide | ADA 2019 | News

Dulaglutide cardioprotective in relatively low-risk REWIND population

The glucagon-like peptide-1 receptor agonist dulaglutide has demonstrated significant cardioprotection in the REWIND trial, despite the trial population being lower risk than usual for cardiovascular outcome trials.

06-10-2019 | Prediabetes | ADA 2019 | News

RISE adult medication results highlight disparity with youth with diabetes

Intensive antidiabetic treatment in adults with newly diagnosed type 2 diabetes slows the decline in beta-cell function, but this is not sustained after the treatment is stopped, show the results of the RISE adult medication study.

Image Credits